ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Slides:

Advertisements

Similar presentations

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Advertisements

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Sabina Kersting, Leo F. Verdonck

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation Is Strongly Associated with Acute Intestinal Graft-versus-Host Disease

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients:

Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results Joseph Pidala, Jongphil.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus- Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta.

Joseph Pidala, Stephanie J

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus- Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft- versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease Joseph Pidala, MD, PhD, Francisca Beato, BS,

What is quality in a transplant program?

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non- Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation Janelle.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study Moshe Yeshurun,

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga Nishihori, Ernesto Ayala, Teresa Field, Hugo Fernandez, Lia Perez, Fred Locke, Melissa Alsina, Jose Leonel Ochoa, Janelle Perkins, Cheryl Tate, Jamie Shapiro, Michelle Conwell, Ryan Bookout, Claudio Anasetti Biology of Blood and Marrow Transplantation Volume 17, Issue 8, Pages 1237-1244 (August 2011) DOI: 10.1016/j.bbmt.2010.12.705 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of grade III-IV aGVHD from date of HCT. Biology of Blood and Marrow Transplantation 2011 17, 1237-1244DOI: (10.1016/j.bbmt.2010.12.705) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of moderate to severe cGVHD (per NIH severity criteria) from date of HCT. Biology of Blood and Marrow Transplantation 2011 17, 1237-1244DOI: (10.1016/j.bbmt.2010.12.705) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Kaplan-Meier plot of OS from date of HCT. Numbers with available data: 3 months lymph (n = 24), CD4 (n = 11); 6 months lymph (n = 23), CD4 (n = 12); 12 months lymph (n = 13), CD4 (n = 8). Biology of Blood and Marrow Transplantation 2011 17, 1237-1244DOI: (10.1016/j.bbmt.2010.12.705) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Absolute lymphocyte and CD4 lymphocyte reconstitution at 3, 6, and 12 months following date of HCT. Biology of Blood and Marrow Transplantation 2011 17, 1237-1244DOI: (10.1016/j.bbmt.2010.12.705) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions